Syntara hopes to emulate the success of Ojjaara, a $2.6 billion home-grown myelofibrosis therapy approved in the US.
Micro-X's 70% climb this week proves momentum is returning to the ASX healthcare sector, notes Morgans analyst Scott Power.
Percheron Therapeutics (ASX:PER) expects to deliver topline data from its Duchenne muscular dystrophy (DMD) trial using ...
Stockhead on MSN17d
Resources Top 5: Excitement builds for Raiden’s Andover lithium results, taking others along for the rideOn the face of it, like your gym bro who puts on 20kgs of pure muscle on what they claim is a diet of coco ... may be ...
AML3D secures A$2.27M order with Tennessee Valley Authority (TVA) for ARCEMY X system. Advanced additive manufacturing for ...
The shift comes at a pivotal time for Meteoric Resources (ASX:MEI), which is confident in ... superpower both willing and able to flex its muscle over international supply chains.
The Federal government is announcing details of its landmark review of Australia’s research and development performance to ...
Discover the agencies that flew in November. Alternatively the agencies that'll be watering down the Christmas punch.
Joint media release with Minister for Education the Hon Jason Clare MPThe Albanese government is announcing details of its ...
The Australian facial injectables industry was estimated to be worth $4.1 billion in 2023, with big corporates including ...
A worldwide shortage of radiologists and Australia’s ageing population underpin the rapid growth of healthcare company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback